Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients

被引:26
作者
Kieler, Markus [1 ]
Unseld, Matthias [1 ]
Bianconi, Daniela [1 ]
Schindl, Martin [2 ]
Kornek, Gabriela V. [1 ]
Scheithauer, Werner [1 ]
Prager, Gerald W. [1 ]
机构
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Comprehens Canc Ctr Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Div Gen Surg, Dept Surg, Comprehens Canc Ctr Vienna,Pancreat Canc Unit, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
关键词
pancreatic ductal adenocarcinoma; treatment landscape; treatment patterns; treatment sequences; new chemotherapy regimens; nanoliposomal irinotecan; nab-paclitaxel; FOLFIRINOX; TREATMENT PATTERNS; GEMCITABINE; OUTCOMES; THERAPY; COHORT; CARE;
D O I
10.3390/jcm9030648
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: New chemotherapy regimens for the treatment of metastatic pancreatic cancer have changed the therapy paradigm. We aimed to assess their impact on the treatment landscape and clinical outcome at our academic institution. Methods: In this single institutional posthoc registry analysis, we assessed characteristics and survival rates from all patients with locally advanced and metastatic pancreatic cancer who started a systemic treatment between 01/2011 and 12/2017. Survival analyses were performed by Kaplan-Meier and Cox proportional hazards model. Results: A total of 301 patients started a systemic treatment in the observation period. In the first line treatment, we observed a shift from the four different main regimens (gemcitabine/nab-paclitaxel, modified FOLFIRINOX, gemcitabine/oxaliplatin +/- erlotinib or gemcitabine alone) to gemcitabine/nab-paclitaxel and modified FOLFIRINOX that add up to more than 80% of administered first line treatments in each of the time cohorts (2011-2013 vs. 2014-2017). The rate for first line modified FOLFIRINOX treatment was balanced between the two groups (19% and 15%). Median overall survival differed significantly between the two time cohorts (8.89 versus 11.9 months, p = 0.035). Survival rates for different first to second line treatment sequences (modified FOLFIRINOX to gemcitabine/nab-paclitaxel, gemcitabine/nab-paclitaxel to fluoropyrimidines plus nanoliposomal irinotecan, or gemcitabine/nab-paclitaxel to fluoropyrimidines plus oxaliplatin) were not significantly different and median overall survival ranged from 14.27 to 15.64 months. Conclusion: Our study provides real-world evidence for the effectiveness of the new chemotherapy regimens and underscores the importance of the choice of the front-line regimen when considering different sequencing strategies.
引用
收藏
页数:15
相关论文
共 31 条
[1]   Patterns of Chemotherapy Use in a US-Based Cohort of Patients with Metastatic Pancreatic Cancer [J].
Abrams, Thomas A. ;
Meyer, Gary ;
Meyerhardt, Jeffrey A. ;
Wolpin, Brian M. ;
Schrag, Deborah ;
Fuchs, Charles S. .
ONCOLOGIST, 2017, 22 (08) :925-933
[2]   Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities [J].
Balachandran, Vinod P. ;
Beatty, Gregory L. ;
Dougan, Stephanie K. .
GASTROENTEROLOGY, 2019, 156 (07) :2056-2072
[3]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[4]   Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature [J].
Caparello, Chiara ;
Vivaldi, Caterina ;
Fornaro, Lorenzo ;
Musettini, Gianna ;
Pasquini, Giulia ;
Catanese, Silvia ;
Masi, Gianluca ;
Lencioni, Monica ;
Falcone, Alfredo ;
Vasile, Enrico .
FUTURE ONCOLOGY, 2016, 12 (07) :901-908
[5]   A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC). [J].
Cheung, Winson Y. ;
Zhang, Hanbo ;
Tang, Patricia A. ;
Spratlin, Jennifer L. ;
Lee-Ying, Richard M. ;
Goodwin, Rachel Anne ;
Meyers, Brandon Matthew ;
Armstrong, Dawn Elizabeth ;
Ramjeesingh, Ravi ;
Vickers, Michael M. ;
Kim, Christina .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[6]   Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010-2016 [J].
Chou, Wen-Chi ;
Chen, Yen-Yang ;
Hung, Chia-Yen ;
Chen, Jen-Shi ;
Lu, Chang-Hsien ;
Chang, Pei-Hung .
CANCER MANAGEMENT AND RESEARCH, 2019, 11 :2119-2127
[7]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[8]   PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy [J].
Gill, Sharlene ;
Ko, Yoo-Joung ;
Cripps, Christine ;
Beaudoin, Annie ;
Dhesy-Thind, Sukhbinder ;
Zulfiqar, Muhammad ;
Zalewski, Pawel ;
Do, Thuan ;
Cano, Pablo ;
Lam, Wendy Yin Han ;
Dowden, Scot ;
Grassin, Helene ;
Stewart, John ;
Moore, Malcolm .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) :3914-+
[9]   Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience [J].
Glassman, Danielle C. ;
Palmaira, Randze L. ;
Covington, Christina M. ;
Desai, Avni M. ;
Ku, Geoffrey Y. ;
Li, Jia ;
Harding, James J. ;
Varghese, Anna M. ;
O'Reilly, Eileen M. ;
Yu, Kenneth H. .
BMC CANCER, 2018, 18
[10]   Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer [J].
Golan, Talia ;
Hammel, Pascal ;
Reni, Michele ;
Van Cutsem, Eric ;
Macarulla, Teresa ;
Hall, Michael J. ;
Park, Joon-Oh ;
Hochhauser, Daniel ;
Arnold, Dirk ;
Oh, Do-Youn ;
Reinacher-Schick, Anke ;
Tortora, Giampaolo ;
Alguel, Hana ;
O'Reilly, Eileen M. ;
McGuinness, David ;
Cui, Karen Y. ;
Schlienger, Katia ;
Locker, Gershon Y. ;
Kindler, Hedy L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :317-327